BAIT
NR5A1
AD4BP, ELP, FTZ1, FTZF1, POF7, SF-1, SF1, SPGF8, SRXY3, RP11-101K10.1
nuclear receptor subfamily 5, group A, member 1
GO Process (8)
GO Function (7)
GO Component (2)
Gene Ontology Biological Process
- cell-cell signaling [TAS]
- gene expression [TAS]
- intracellular receptor signaling pathway [TAS]
- positive regulation of male gonad development [IDA]
- positive regulation of transcription from RNA polymerase II promoter [IMP]
- primary sex determination [TAS]
- regulation of steroid biosynthetic process [TAS]
- transcription initiation from RNA polymerase II promoter [TAS]
Gene Ontology Molecular Function- DNA binding [IDA]
- RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity [IDA]
- enzyme binding [IPI]
- ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity [TAS]
- phospholipid binding [IDA]
- protein binding [IPI]
- transcription coactivator activity [TAS]
- DNA binding [IDA]
- RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity [IDA]
- enzyme binding [IPI]
- ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity [TAS]
- phospholipid binding [IDA]
- protein binding [IPI]
- transcription coactivator activity [TAS]
Gene Ontology Cellular Component
- nucleoplasm [TAS]
- nucleus [IDA]
Homo sapiens
PREY
P2RY6
P2Y6, PP2891
pyrimidinergic receptor P2Y, G-protein coupled, 6
GO Process (1)
GO Function (1)
GO Component (2)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Nat. Biotechnol. Mar. 20, 2017; 0(); [Pubmed: 28319085]
Quantitative Score
- -2.988 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Curated By
- BioGRID